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BACKGROUND: Thalidomide has potent anti-inflammatory and anti-angiogenic properties. It was evaluated in combination with
chemotherapy in two randomised placebo-controlled trials in patients with small cell lung cancer (SCLC, n¼ 724) and advanced non-
small cell lung cancer (NSCLC, n¼ 722). Neither study demonstrated an improvement in overall survival with the addition of
thalidomide to chemotherapy. This study investigated circulating angiogenic biomarkers in a subset of these patients.
METHODS: Serial plasma samples were collected in a cohort of patients enrolled in these two trials (n¼ 95). Vascular endothelial
growth factor (VEGF), soluble truncated form of VEGF receptor-2 (sVEGFR-2), interleukin-8 (IL-8), tumour necrosis factor-a
(TNF-a), basic fibroblast growth factor (bFGF) and soluble intercellular adhesion molecule-1 (sICAM-1) levels were measured by
enzyme-linked immunosorbent assays. Results were correlated with patient clinical data including stage, response rate and
progression-free survival (PFS).
RESULTS: Baseline biomarker levels were not significantly different between SCLC and NSCLC. For pooled treatment groups, limited
stage SCLC was associated with lower baseline VEGF (P¼ 0.046), sICAM-1 (P¼ 0.008) and IL-8 (P¼ 0.070) than extensive stage
disease. Low baseline IL-8 was associated with a significantly improved PFS in both SCLC and NSCLC (P¼ 0.028), and a greater
reduction in IL-8 was associated with a significantly improved tumour response (P¼ 0.035). Baseline angiogenic factor levels,
however, did not predict response to thalidomide.
CONCLUSION: Circulating angiogenic biomarkers did not identify patients who benefited from thalidomide treatment.
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Angiogenesis is a critical step in tumour growth, and the
development of angiogenic-targeted therapy is the focus of intense
research. High levels of vascular endothelial growth factor (VEGF)
and tumour vessel density are poor prognostic markers in both
small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC) (Herbst et al, 2005). VEGF is a key regulator of angio-
genesis and the humanised VEGF monoclonal antibody bevacizumab
has been shown to prolong survival when given in combination
with chemotherapy in NSCLC (Sandler et al, 2006).
Thalidomide is a synthetic glutamic acid derivative, with
immunomodulatory and anti-proliferative activity with proven
clinical activity in multiple myeloma and myelodysplastic syn-
dromes (Melchert and List, 2007). It inhibits tumour necrosis
factor-a (TNF-a) production by increasing degradation of TNF-a
mRNA. It inhibits nuclear factor kappa B, a key regulator of TNF-a
and interleukin-8 (IL-8) production, and reduces the expression
of cell surface markers such as soluble intercellular adhesion
molecule-1 (sICAM-1) and E-selectin. Thalidomide is also a potent
anti-angiogenic agent (D’Amato et al, 1994) due to suppression
of VEGF and basic fibroblast growth factor (bFGF) secretion
and inhibition of endothelial cell proliferation. VEGF receptor 2
(VEGFR2), principally expressed on the endothelial cell surface,
mediates the pro-angiogenic response to VEGF (Shibuya, 2006).
VEGFR2 is also found in a soluble truncated form of VEGF
receptor-2 (sVEGFR2), which has been studied as a biomarker of
tumour angiogenesis (Ebos et al, 2008). Significant decreases in
sVEGFR2 plasma levels have been reported in clinical studies
with anti-angiogenic therapy for NSCLC (Hanrahan et al, 2010;
Nikolinakos et al, 2010), notably with tyrosine kinase inhibitors.
It is not known whether the anti-angiogenic properties of thali-
domide alter circulating sVEGFR2 levels.
Thalidomide combined with chemotherapy in SCLC was well
tolerated in a single arm phase II study with a response rate of
17/25 (68%) (Lee et al, 2008). Thalidomide 200mg once daily was
therefore evaluated in combination with standard chemotherapy in
two prospective phase III-randomised, double-blind, placebo-
controlled trials in patients with SCLC (Lee et al, 2009b) and
advanced NSCLC (Lee et al, 2009a) that enrolled a total of 1446
patients. Neither study showed that thalidomide in combination
with chemotherapy increased overall survival (OS) compared with
Received 28 November 2011; revised 23 January 2012; accepted 26
January 2012; published online 21 February 2012
*Correspondence: Dr RJ Young; E-mail: r.j.young@sheffield.ac.uk
5These authors contributed equally to this work.
British Journal of Cancer (2012) 106, 1153 – 1159
& 2012 Cancer Research UK All rights reserved 0007 – 0920/12
www.bjcancer.com
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
chemotherapy alone. However, a significant increase in throm-
boembolic events was seen in patients randomised to thalidomide.
Serial plasma samples were collected in an unselected cohort of
patients enrolled in these two lung cancer studies. Here, we
describe the analysis of circulating angiogenic biomarkers in this
sample set. The objectives of this study were to determine the
relationship between baseline angiogenic biomarkers, and other
prognostic factors and outcome, to determine the interaction between
angiogenic factors and treatment, and to investigate changes in
angiogenic biomarkers due to thalidomide treatment.
PATIENTS AND METHODS
Patients and study design
The two multicenter, randomised, phase III clinical trials are des-
cribed in detail elsewhere (Lee et al, 2009a, b). Briefly, between May
2003 and September 2008, 724 patients with limited or extensive stage
SCLC were treated with up to six cycles of carboplatin and
etoposide chemotherapy every 3 weeks, and randomly assigned
to receive either oral thalidomide or matching placebo for up to
2 years (LLCG study 12, ISRCTN16174527). A total of 722 patients
with stage IIIB or stage IV NSCLC were treated with up to four
cycles of gemcitabine and carboplatin chemotherapy every 3 weeks
and randomly assigned to receive either oral thalidomide or matching
placebo for up to 2 years (LLCG study 14, ISRCTN77341241). Both
clinical studies were approved by the relevant ethics authorities
and written informed consent was obtained from all patients.
Plasma sample collection for biomarker analysis was planned from
120 patients (60 from each study) in selected participating centres.
Plasma sample collection for the biomarker study was optional and
only patients who consented to this are included in this analysis.
Plasma sample collection and analyses
Plasma samples were prepared from venous blood samples col-
lected before treatment cycles 1 (C1) and 4 (C4). Samples were
collected in EDTA tubes, centrifuged at 2000 r.p.m. for 10min and
stored at 801C until analysis. Samples were collected from 2003
to 2006 and stored at University College London until analysis at
the University of Sheffield in 2011. Analysis was performed to
measure levels of the angiogenic factors VEGF, sVEGFR-2, bFGF,
TNF-a, IL-8 and sICAM-1, selected because of the known mechanism
of thalidomide activity. During sample analysis, investigators were
blinded to outcome and treatment group. Angiogenic factors
were analysed by enzyme-linked immunosorbent assays (ELISA)
(Quantikine, R&D Systems Europe Ltd, Abingdon, UK), as per the
manufacturers’ instructions. A standard concentration curve was
produced for each ELISA plate with the manufacturers’ control
solution and used to calculate plasma concentrations. Serial
samples were assessed on the same ELISA plate to reduce inter-
experimental variability. Baseline levels and changes at C4 were
correlated with stage, response rate and progression-free survival
(PFS). Levels of angiogenic factors were compared between
patients on thalidomide and those on placebo to investigate
changes as a consequence of thalidomide therapy.
Statistical methods
Logarithmic transformation to a normal distribution was per-
formed prior to analysis of baseline VEGF, bFGF, TNF-a, IL-8 and
sICAM-1. Baseline sVEGFR-2 and changes in angiogenic factor
levels (from C1 to C4) were normally distributed without tran-
sformation. The independent samples t-test was used to assess
differences between SCLC and NSCLC. The paired t-test was used
to analyse changes in angiogenic factor levels from C1 to C4. The
independent samples t-test was also used to analyse associations
between angiogenic factor levels, tumour stage and best response.
PFS was measured from the date of randomisation to the date of
progression of disease, or of death from any cause. Differences in
PFS were assessed using measurements of angiogenic factors
expressed both as a continuous variable and dichotomised at
the median to distinguish high and low groups. Cox-regression
analysis was used to calculate hazard ratios (HR) for PFS, and
multivariate analysis of survival was performed using the back-
ward selection method. Statistical analysis was performed using
SPSS 16.0 for Windows (IBM, Armonk, NY, USA).
RESULTS
Patient population
In this biomarker study, 164 plasma samples were analysed from
95 patients. About 100% of patients contributed baseline (C1)
samples and 73% (69/95) at C4. There were a similar number of
patients with SCLC and NSCLC, and in the thalidomide and
placebo groups. The patients’ characteristics are compared with
those from the two parent clinical trials in Table 1. The distribu-
tion of age, gender and stage were similar to the clinical trial
population but the biomarker study population was of slightly
better performance status (not significant) and had a different
pattern of NSCLC histological subtypes.
At the time of database lock, 87 of the 95 patients (92%)
included in this biomarker study had progressed and 83/95 (87%)
had died. As in the parent clinical trials, a comparison of the survival
data for the biomarker study population showed no survival advantage
for thalidomide compared with placebo in SCLC, NSCLC or the
combined group. Median OS was 11.5 and 10.7 months for thali-
domide and placebo groups, respectively, with an HR of 1.25 (95%
CI 0.81–1.94; P¼ 0.32). Median PFS was 6.8 and 7.3 months for
thalidomide and placebo groups, respectively, with an HR of 1.24
(95% CI 0.80–1.90; P¼ 0.36). There was also no significant differ-
ence in response rate by treatment group (partial response (PR):
thalidomide (49%) vs placebo (36%); P¼ 0.19).
In this study, earlier tumour stage was associated with a signifi-
cantly improved PFS in SCLC, but not NSCLC. The HR for progression
in SCLC with extensive disease (ED) was 2.70 (95% CI 1.40–5.21;
P¼ 0.003). In NSCLC, the HR for PFS with stage IV was 0.95 (95%
CI 0.52–1.73; P¼ 0.86). A trend towards decreased PFS with deter-
iorating WHO performance status was seen in SCLC with an HR
1.51 (95% CI 0.98–2.33; P¼ 0.060), although in this study population
the number of patients with poor performance status was small.
In the clinical trials, patients treated with thalidomide had an
increased risk of a thrombotic event compared with patients receiving
placebo. However, in this sub-study the difference was not signifi-
cant (20% of patients developed thrombosis on thalidomide
compared with 17% on placebo; P¼ 0.89). The small sample size
prohibited biomarker comparisons between thrombotic sub-groups.
Analysis of baseline angiogenic biomarkers for pooled
treatment groups
There were no statistically significant differences between patients
with SCLC and NSCLC in angiogenic factors at baseline (C1)
(Table 2). In SCLC, baseline VEGF and sICAM-1 were, on average,
significantly lower in limited disease (LD) compared with ED, and
there was a suggestion of lower IL-8 in LD (Table 3). There were no
significant differences in baseline angiogenic factors between NSCLC
stage IIIB and stage IV. There were no significant differences in
baseline factors between patients who had a PR to treatment and
those with stable (SD) or progressive disease (PD) for SCLC, NSCLC
or the combined group (Table 4).
Survival analysis showed a significant increased risk of progres-
sion with high baseline IL-8 for SCLC and NSCLC patient groups
combined, with an HR of 1.61 (95% CI 1.05–2.47; P¼ 0.028)
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(Table 5). Subgroup survival analysis showed high baseline IL-8
was associated with a significantly worse prognosis in SCLC but
not NSCLC, with an HR for progression of 1.94 (95% CI 1.05–3.59;
P¼ 0.036). Subgroup analysis also identified a significant relation-
ship between PFS and baseline sICAM-1 in SCLC for pooled
treatment arms but not in NSCLC, with an HR for progression with
high baseline sICAM-1 in SCLC of 2.20 (95% CI 1.16–4.18;
P¼ 0.016). Similarly, there was a suggestion of an increased risk of
progression with high baseline VEGF in SCLC, but not NSCLC;
HR¼ 1.79 (95% CI 0.97–3.30; P¼ 0.063). No other significant
differences were seen between PFS and baseline angiogenic factors
in subgroup or pooled analysis, irrespective of the angiogenic
factors being treated as categorical or continuous data.
In multivariate analysis of survival including baseline angio-
genic factors, stage and performance status, stage was the only
significant prognostic factor in SCLC.
Changes in angiogenic biomarkers after chemotherapy
for pooled treatment groups
In the combined SCLC and NSCLC data set, there were significant
changes in IL-8 and bFGF levels between C1 and C4 (Figure 1A).
Table 1 Patient characteristics of the biomarker population, shown by tumour type and the parent clinical population
SCLC NSCLC SCLC and NSCLC combined Parent studies combined
n % N % n % N %
Total 47 100 48 100 95 100 1446 100
Treatment
Thalidomide 25 53 24 50 49 52 737 51
Placebo 22 47 24 50 46 48 709 49
Age at random assignment
X50 45 96 41 85 86 91 1342 93
Gender
Male 29 62 34 71 63 66 877 61
Female 18 38 14 29 32 34 569 39
Stage
Limited stage/stage IIIb 20 43 22 46 42 44 690 48
Extensive stage/stage IV 27 57 26 54 53 56 756 52
WHO performance status
0 13 28 16 33 29 31 344 24
1 24 51 32 67 56 59 833 57
2 8 17 0 0 8 8 227 16
3 2 4 0 0 2 2 42 3
Cell type (NSCLC only)
Squamous cell 11 23 239 33
Adenocarcinoma 17 35 268 37
Large cell 6 13 47 7
Other 14 29 168 23
Abbreviations: NSCLC¼ non-small cell lung cancer; SCLC¼ small cell lung cancer.
Table 2 Angiogenic biomarker levels at baseline (C1) and pre-cycle 4 (C4) for SCLC and NSCLC
SCLC NSCLC
Angiogenic factor Time n Median (pgml1) Range (pgml1) n Median (pgml1) Range (pgml1) P
VEGF C1 47 144.6 23.2–912.0 48 149.6 10.3–1360.8 0.58
C4 33 145.5 22.4–1055.1 36 129.9 21.6–3051.9 0.93
sVEGFR-2 C1 47 7833.8 90.0–13711.0 48 8243.0 3302.0–14 515.0 0.15
C4 33 8061.9 530.0–7092.2 36 7400.0 3780.0–14 336.3 0.35
IL-8 C1 47 23.0 0.0–335.8 48 30.7 5.8–198.0 0.08
C4 33 15.2 3.5–104.3 36 22.4 1.6–240.0 0.25
TNF-a C1 44 23.7 7.8–63.5 46 31.4 0.0–121.0 0.97
C4 30 22.6 11.4–60.0 35 28.4 0.0–112.3 0.98
sICAM-1a C1 46 321.1 160.3–1307.4 47 436.6 132.9–933.2 0.11
C4 31 326.8 195.8–804.6 35 434.3 165.0–1127.1 0.039
bFGF C1 46 12.0 0.6–181.3 46 12.6 0.0–143.1 0.30
C4 31 11.9 0.0–176.0 35 17.1 0.0–383.4 0.94
Abbreviations: bFGF¼ basic fibroblast growth factor; IL-8¼ interleukin-8; NSCLC¼ non-small cell lung cancer; SCLC¼ small cell lung cancer; sICAM-1¼ soluble intercellular
adhesion molecule-1; sVEGFR-2¼ soluble truncated form of vascular endothelial growth factor receptor-2; TNF-a¼ tumour necrosis factor-a; VEGF¼ vascular endothelial
growth factor. The P-value was calculated using the independent t-test, comparing the mean values for SCLC with NSCLC, following logarithmic transformation of the data to
achieve a normal distribution where necessary. P-values o0.05 are highlighted in bold. asICAM-1 was measured in ngml1.
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There was a decrease of IL-8 14.6 pgml1 (±7.3; P¼ 0.049) and bFGF
increased by 14.5pgml1 (±6.5; P¼ 0.029). Only sICAM-1 demon-
strated a significant difference between SCLC and NSCLC in mean
change in factor level. In SCLC, sICAM-1 reduced by 70.4 ngml1
(±51.0) whereas in NSCLC sICAM-1 increased by 60.7 ngml1
(±34.0) (P¼ 0.033). Changes in other investigated angiogenic factors
did not differ significantly between SCLC and NSCLC (Figure 1B).
Reduction in IL-8 for pooled treatment arms was associated
with response in both SCLC and NSCLC. Patients with a PR had a
larger decrease in IL-8 from C1 to C4 compared with those with SD
and PD. Mean decrease in IL-8 from patients with PR was
31.4 pgml1 (±11.3) compared with 0.8 pgml1 (±8.9) with SD
and PD (P¼ 0.035). There was a suggestion of a trend on further
separating SD 1.5 pgml1 (±10.8) and PD þ 2.1 pgml1
(±13.8), (one-way ANOVA, P¼ 0.109), but the number of patients
with PD were small (n¼ 8). Changes in the levels of other
angiogenic factors for pooled treatment arms did not predict
tumour response in SCLC, NSCLC or the combined histology
group (Figure 1C). Furthermore, there were no significant
differences in PFS by change in angiogenic factors (Table 5).
Table 3 Comparison of SCLC and NSCLC baseline factors by tumour stage
SCLC NSCLC
Angiogenic factor Stage Median Range P Median Range P
VEGF LD/IIIB 121.8 23.2–308.1 0.046 156.5 31.3–952.9 0.77
ED/IV 151.3 27.0–912.0 146.3 59.2–1360.8
sVEGFR-2 LD/IIIB 7892.5 507.5–13711.0 0.95 8372.0 3302.0–11 760.0 0.96
ED/IV 7580.0 90.0–11346.3 7317.1 4271.0–14 515.0
IL-8 LD/IIIB 12.1 0.0–335.8 0.07 24.2 8.3–198.0 0.93
ED/IV 24.5 1.8–244.8 32.3 8.2–146.7
TNF-a LD/IIIB 22.9 9.1–63.5 0.68 38.6 2.2–121.0 0.58
ED/IV 24.3 7.8–43.7 24.8 0.0–96.1
sICAM-1a LD/IIIB 305.5 168.1–508.6 0.008 383.3 160.7–792.4 0.31
ED/IV 388.4 160.3–1307.4 443.3 132.9–933.2
bFGF LD/IIIB 9.1 0.6–73.0 0.13 7.1 0.0–143.1 0.77
ED/IV 19.7 1.0–181.3 12.6 0.0–112.5
Abbreviations: bFGF¼ basic fibroblast growth factor; ED¼ extensive disease; IL-8¼ interleukin-8; LD¼ limited disease; NSCLC¼ non-small cell lung cancer; SCLC¼ small cell
lung cancer; sICAM-1¼ soluble intercellular adhesion molecule-1; sVEGFR-2¼ soluble truncated form of vascular endothelial growth factor receptor-2; TNF-a¼ tumour
necrosis factor-a; VEGF¼ vascular endothelial growth factor. P-values were calculated using the independent t-test, following logarithmic transformation where necessary.
P-values o0.05 are highlighted in bold. asICAM-1 measured in ngml1.
Table 4 Baseline levels (C1) of angiogenic factors according to best response
Angiogenic factor Best response Median values at C1 in pgml1 (range) P
VEGF PR 155.1 (23.2–1360.8) 0.84
SD and PD 138.6 (10.3–1360.8)
sVEGFR2 PR 8049.4 (90.0–11 892.5) 0.41
SD and PD 7936.4 (656.3–14 515.0)
IL-8 PR 23.2 (0.0–335.8) 0.57
SD and PD 30.7 (2.9–174.6)
TNFa PR 26.3 (2.2–121.0) 0.26
SD and PD 25.5 (0.0–87.4)
sICAM1a PR 354.5 (160.3–1307.4) 0.81
SD and PD 377.6 (132.9–1056.7)
bFGF PR 10.3 (0.0–143.11) 0.67
SD and PD 13.9 (0.0–181.3)
Abbreviations: bFGF¼ basic fibroblast growth factor; IL-8¼ interleukin-8; NSCLC¼ non-small cell lung cancer; PD¼ progressive disease; PR¼ partial response; SCLC¼ small
cell lung cancer; SD¼ stable disease; sICAM-1¼ soluble intercellular adhesion molecule-1; sVEGFR-2¼ soluble truncated form of vascular endothelial growth factor receptor-2;
TNF-a¼ tumour necrosis factor-a; VEGF¼ vascular endothelial growth factor. P-values were calculated using the independent t-test and confirmed using logistic regression.
asICAM-1 measured in ngml1.
Table 5 Angiogenic biomarker effects on PFS for SCLC and NSCLC patients combined
Angiogenic factor
Hazard ratio (95% CI) by
angiogenic factor at baseline P
Hazard ratio (95% CI) by
change in factor from C1 to C4 P
VEGF 1.17 (0.76–1.78) 0.48 0.80 (0.49–1.31) 0.38
sVEGFR2 1.07 (0.70–1.64) 0.75 1.24 (0.76–2.03) 0.39
IL-8 1.61 (1.05–2.47) 0.028 0.78 (0.48–1.29) 0.33
TNFa 0.77 (0.50–1.20) 0.25 1.42 (0.85–2.36) 0.19
sICAM1 1.35 (0.87–2.07) 0.18 0.92 (0.55–1.52) 0.73
bFGF 1.04 (0.67–1.60) 0.88 0.89 (0.53–1.48) 0.65
Abbreviations: bFGF¼ basic fibroblast growth factor; CI¼ confidence interval; IL-8¼ interleukin-8; NSCLC¼ non-small cell lung cancer; PFS¼ progression-free survival;
SCLC¼ small cell lung cancer; sICAM-1¼ soluble intercellular adhesion molecule-1; sVEGFR-2¼ soluble truncated form of vascular endothelial growth factor receptor-2;
TNF-a¼ tumour necrosis factor-a; VEGF¼ vascular endothelial growth factor. Factors were dichotomised around the median value into high and low groups. P-values o0.05
are highlighted in bold.
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Angiogenic factors and thalidomide
Biomarker levels were compared at C1 to adjust for differences
between treatment groups at baseline. Only baseline sVEGFR-2
was significantly different between the two treatment groups
(mean sVEGFR-2 at C1 in the thalidomide arm was 7080.7 pgml1
(±2410.3) compared with 8505.0 pgml1 (±2833.2) in the placebo
arm (P¼ 0.010)). No significant differences were seen in the mean
change in angiogenic factor levels from C1 to C4 between thali-
domide and placebo groups (Figure 1D).
Subgroup analysis was performed to explore whether baseline
levels of angiogenic biomarkers predicted response to thalidomide.
For patients who received thalidomide, there were no significant differ-
ences in tumour response or PFS between those with high baseline
levels compared with those with low baseline levels (Table 6).
Analysis to quantify the relationship (i.e., test for interaction)
between thalidomide and biomarker was therefore not supported.
Finally, the parent clinical trial of thalidomide in NSCLC suggested
a potential survival benefit for thalidomide in patients with squa-
mous histology. Biomarker analysis was limited because the number
of patients with squamous NSCLC was small (n¼ 11). Compared
with other NSCLC histology patients, those with squamous disease
had a significantly higher bFGF at baseline (median bFGF with
squamous histology was 31.5 pg ml1 (range 3.3–143.1) compared
with 6.9 pgml1 (range 0.0–112.5) with other NSCLC histology
(P¼ 0.022)), and a suggestion of a higher VEGF (median VEGF
with squamous histology was 265.7 pgml1 (range 50.2–1360.8)
compared with 141.2 pgml1 (range 31.3–761.9) with other NSCLC
histology (P¼ 0.07)). There were no significant differences in change
in angiogenic factor levels from C1 to C4 between squamous and
other NSCLC histology.
DISCUSSION
Thalidomide is a drug with multiple mechanisms of action including
inhibition of angiogenesis. Treatment with thalidomide failed to
provide any survival benefit in two large phase III trials in SCLC
and NSCLC (Lee et al, 2009a, b). We studied pre-treatment and pre-
cycle four plasma levels of VEGF, sVEGFR-2, IL-8, TNF-a, sICAM-1
and bFGF in an unselected cohort of patients from these trials to
analyse the biological effects of thalidomide treatment, and to inve-
stigate their utility as biomarkers in lung cancer. The biomarker study
population was broadly representative of the clinical trial population,
although only 6.6% of patients recruited to the two clinical lung
cancer studies had samples collected for analysis of angiogenic
growth factors; and this is an important limitation of our study.
The biology of SCLC and NSCLC is different, and in our analysis
we considered these groups separately. However, analysis of the
combined data set was also justified. Differences between SCLC
and NSCLC at baseline (C1) and in the change to angiogenic factor
levels from C1 to C4 (excluding sICAM-1) were not statistically
significant. Furthermore, an important aim of this study was to
investigate changes in angiogenic factors as a consequence of
thalidomide treatment, and it was predicted these changes would
be similar in both SCLC and NSCLC patients.
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Figure 1 Changes in angiogenic biomarkers between baseline and C4.
Each figure shows mean changes expressed as a percentage of baseline
values. (A) Changes in angiogenic biomarkers for the combined data set.
P-values were calculated to compare C1 with C4 values using the paired
t-test. (B) Changes in angiogenic biomarkers for SCLC and NSCLC.
P-values were calculated using the independent t-test. (C) Changes in
angiogenic biomarkers according to best tumour response. P-values were
calculated using the independent t-test. (D) Changes in angiogenic
biomarkers for thalidomide and placebo groups. P-values were calculated
using the independent t-test; none were significant. *Po0.05, error bars
represent 1 standard error of the mean.
Table 6 Angiogenic biomarker effects on PFS for thalidomide
Angiogenic
factor
Hazard ratio (95% CI) by angiogenic
factor at baseline P
VEGF 0.89 (0.49–1.59) 0.67
sVEGFR2 1.49 (0.82–2.71) 0.20
IL-8 1.33 (0.75–2.38) 0.33
TNFa 0.95 (0.51–1.74) 0.86
sICAM1 0.82 (0.44–1.51) 0.52
bFGF 1.00 (0.55–1.81) 0.99
Abbreviations: bFGF¼ basic fibroblast growth factor; CI¼ confidence interval;
IL-8¼ interleukin-8; PFS¼ progression-free survival; sICAM-1¼ soluble intercellular
adhesion molecule-1; sVEGFR-2¼ soluble truncated form of vascular endothelial
growth factor receptor-2; TNF-a¼ tumour necrosis factor-a; VEGF¼ vascular
endothelial growth factor. Factors were dichotomised around the median value into
high and low groups.
Angiogenic biomarkers and thalidomide in lung cancer
RJ Young et al
1157
British Journal of Cancer (2012) 106(6), 1153 – 1159& 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
A wide range of values was seen in the levels of angiogenic
biomarkers quantified in this study, similar to that reported in
other biomarker studies in lung cancer (Dowlati et al, 2008; Hanrahan
et al, 2010). Low baseline levels of IL-8, VEGF and sICAM-1 were
associated with limited stage SCLC. These factors were also associated
with an improved PFS, although in multivariate analysis only tumour
stage was significant. Comparisons between baseline angiogenic
factors in stage IIIB and stage IV NSCLC were not significant,
which is unsurprising as early stage NSCLC were excluded from
the clinical trial. Changes from C1 to C4 were seen in IL-8 and
sICAM-1 levels, and changes in IL-8 were associated with tumour
response in the combined NSCLC and SCLC data set.
An important effect of thalidomide is to decrease TNF-a through
degradation of its mRNA (Melchert and List, 2007). However, in
this study there was no difference in TNF-a at C4 between those on
thalidomide and those on placebo. Overall TNF-a levels increased
on study and increased more in patients on thalidomide than in
those on placebo, although this difference was not significant.
TNF-a expression did not correlate with the other investigated
angiogenic factors; however, the anti-angiogenic activity of
thalidomide is independent of its TNF-a effect (Dredge et al,
2002) and is mediated through reduced secretion of angiogenic
growth factors including VEGF and inhibition of endothelial cell
proliferation (Melchert and List, 2007). We found no significant
differences in the change to angiogenic biomarker levels from C1
to C4 between thalidomide and placebo groups; furthermore, high
baseline levels of angiogenic factors were not associated with
response to thalidomide. We conclude there were no detectable
effects on angiogenic factor levels as a result of thalidomide
therapy in this study. Published data on the effects of thalidomide
therapy on circulating angiogenic biomarkers is conflicting. Phase
II studies of thalidomide in multiple myeloma have concluded that
a higher baseline VEGF levels were associated with response to
treatment ((Mileshkin et al, 2007), and clinical responses
associated with decreases in VEGF and bFGF levels (Bertolini
et al, 2001). Other studies of thalidomide in multiple myeloma
have observed no change (Thompson et al, 2003), or even increase
in VEGF and bFGF levels with treatment (Hatjiharissi et al, 2004).
Two parallel non-randomised phase II studies in patients with
malignant mesothelioma treated with single agent thalidomide or
thalidomide combined with carboplatin and gemcitabine reported
pre-treatment VEGF serum levels were prognostic, and increases
in VEGF levels on treatment were associated with a worse
prognosis (Kao et al, 2012). A small phase II trial of neo-adjuvant
carboplatin–gemcitabine chemotherapy with thalidomide in 15
patients with stage IIB–IIIA NSCLC showed that a higher baseline
IL-8 was associated with a significantly greater risk of disease
recurrence post-operatively, although an increase in IL-8 after
treatment was associated with a reduced risk of recurrence (Dudek
et al, 2009). Biomarker levels in this study of patients with
relatively low volume disease were lower than in our NSCLC
patients with stage IIIB and IV disease.
IL-8 emerged as a factor of interest in our analysis. Through the
G protein-coupled receptors CXCR1 and CXCR2, it exerts both
inflammatory and angiogenic responses, and can directly stimulate
cancer cell proliferation and survival (Waugh and Wilson, 2008).
The expression of IL-8 and its receptors has been catalogued in a
panel of SCLC and NSCLC cell lines, and was identified
as an autocrine and/or paracrine growth factor in these cells
(Zhu et al, 2004). In a study of resected NSCLC, IL-8 protein
expression predominated in tumour cells and to a lesser degree in
tumour-associated macrophages. Expression of IL-8 mRNA
correlated with tumour micro-vessel density, and increased
expression was significantly associated with more advanced stage
disease, earlier recurrence and reduced OS (Yuan et al, 2000).
Increases in serum IL-8 on treatment were associated with a
reduced PFS in a recent study of vandetanib and chemotherapy in
NSCLC (Hanrahan et al, 2010); however, a small study in SCLC
identified no relationship with serum IL-8 and tumour stage,
chemotherapy response or PFS (Tas et al, 2006). Further studies
are required to clarify the relationship between IL-8 and tumour
burden in lung cancer, and how levels change with systemic
therapy.
In this study, the interval between plasma samples was relatively
long (9 weeks). A study of the anti-angiogenic tyrosine kinase
inhibitor vandetanib in NSCLC demonstrated that changes in
biomarker levels occurred early in treatment (day 8) and were later
lost in the noise of chemotherapy-induced changes (Hanrahan
et al, 2010). Thus, early changes in angiogenic biomarkers could
have been missed in our study. The absence of detectable changes
in angiogenic factors with thalidomide therapy seen in this study,
and lack of therapeutic benefit identified in the clinical lung cancer
studies might have been due to an inadequate thalidomide dose,
although this dose was sufficient to significantly increase throm-
boembolic events. A phase III study comparing 400mg daily of
thalidomide with placebo in patients with chemo-responsive SCLC,
however, also failed to demonstrate a significant improvement in
survival, but was associated with an increased toxicity (Pujol et al,
2007).
The response to angiogenesis-targeted therapy in lung cancer
clinical trials has thus far proved disappointing (Ulahannan and
Brahmer, 2011). A predictive biomarker is required to target the
subpopulation of patients who can benefit from these agents. Further
studies are required to investigate the direct biological effects of
these drugs on tumours in patients. Circulating biomarkers are a
surrogate measure of these changes but their collection and
analysis is both more feasible and practical, and it is hoped it will
enable identification of patient sub-populations sensitivity to
therapy (Reinmuth et al, 2010). In our analysis of an unselected
cohort of patients from two lung cancer studies of chemotherapy
with or without thalidomide, significant changes were seen in
angiogenic biomarker levels in association with treatment. However,
changes in factor levels could not be attributed to thalidomide
therapy, and elevated baseline angiogenic factors did not predict
response to thalidomide. The use of IL-8 as a biomarker in lung
cancer requires validation in larger studies.
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